Research and Markets: 7 Vascular Targeting Drugs in Clinical Trials with Many More in...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of The Business Development and R&D Database: Vascular Targeting to their offering.

Save time and money through faster results! This is a unique database for the analysis of the development

Drugs that work to withdraw tumors of a blood supply fall into two groups, angiogenesis inhibitors and vascular targeting agents that probably have an advantage in that they are capable to harm the existing tumor vasculature, rather than prevent further formation by angiogenesis.

There are currently at least seven vascular targeting drugs in clinical trials with many more in pre-clinical development. Three small molecule vascular targeting agents have reached phase II clinical studies (all three compounds act by inhibiting tubulin polymerization); combretastatin A4 phosphate (CA4P, OXiGENE), ZD6126 (Angiogene/AstraZeneca) and AVE-8602 (Aventis/Ajinomoto). Other companies with vascular targeting related R&D are; Adherex Technologies Inc., Peregrine Pharmaceuticals, Maxim Pharmaceuticals, Nereus Pharmaceuticals, Antisoma plc, MediciNova Inc., Munich Biotech AG, Genzyme, Abtech, Schering AG, Targa Therapeutics, Millennium Pharmaceuticals, Imclone Systems, Virexx and more.

A significant advantage with these CD-ROM searchable databases is that they provide you with the most well structured information available today (see below). Each pipeline drug/project has been carefully defined and classified into categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, these CD-ROM searchable databases provide you with a better overview and specific search capabilities.

"Business Development and R&D Database: Vascular Targeting" that has been compiled to enable your independent and unbiased analysis of progress, pitfalls and competition of drugs utilizing a vascular targeting and/or antiangiogenesis effects. The information in the database has carefully been selected and structured to provide the most optimal and timesaving platform to work from. The database contains extensive corporate, R&D, patent and business information.

Features:

--Get rid of duplicate hits

--Get rid of false positive hits

--Unique and improved definitions

Generally, the database is structured into four sections:

--R&D activities

--Related patents

--Collaborations

--Company profiles

The R&D information is structured into 11 searchable segments:

--Investigator

--Drug name

--Combinatory drugs

--Developmental stage

--Indication

--Sub-indication

--Therapy given

--Drug Effects

--Mechanisms/Targets

--General comments

--Source of data

The collaboration information is structured into 5 searchable segments:

--Collaborators

--Product

--Developmental stage

--Type of collaboration

--Type of terms

For more information visit http://www.researchandmarkets.com/reports/c6773